TGRX-814
/ Shenzhen TargetRx
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 10, 2024
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Shenzhen TargetRx, Inc. | Not yet recruiting ➔ Recruiting
Combination therapy • Enrollment open • Monotherapy • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology
January 16, 2024
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
(clinicaltrials.gov)
- P1/2 | N=30 | Not yet recruiting | Sponsor: Shenzhen TargetRx, Inc.
Combination therapy • Monotherapy • New P1/2 trial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology
1 to 2
Of
2
Go to page
1